A chaotic nine months at the FDA has witnessed the toppling of more than half the agency’s senior leadership, the axing of 3,500 more staff and a safety scandal that upended the gene therapy sector, which…
Consistency in the Chaos: FDA Approvals Within Average Range as Q4 Kicks Off
